

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1 (Original). A naturally occurring low molecular weight adenosine A3 receptor agonist (LMW-A3RAg).

2 (Original). The LMW-A3RAg of Claim 1, obtainable from a vertebrate tissue or a vertebrate-derived cell by extraction in a liquid medium.

3 (Original). The LMW-A3RAg of Claim 2, obtainable from muscle tissue.

4 (Original). The LMW-A3RAg of Claim 1, obtainable from medium conditioned by vertebrate source cells.

5 (Original). The LMW-A3RAg of Claim 4, wherein said source cells are muscle cells.

6 (Original). The LMW-A3RAg of Claim 4, wherein said source cells are white blood cells.

7 (Original). The LMW-A3RAg of Claim 1, which is resistant to degradation by adenosine deaminase.

The LMW-A3RAg of Claim 1, having the following characteristics:

- (i) it is obtainable from animal-derived tissue or cells;
- (ii) it filters through a filter with a maximal molecular weight cut-off of about 3,000 Daltons;
- (iii) it is water soluble, heat stable, non-proteinaceous and resistant to adenosine deaminase activity.

9 (Original). A synthetic molecule having the same chemical structure as the agonist of Claim 1.

10 (Original). A pharmaceutical composition comprising as an active ingredient, a therapeutically effective amount of at least one naturally occurring LMW-A3RAg and a pharmaceutically acceptable excipient.

11 (Original). A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of the molecule of Claim 9.

12 (Original). The pharmaceutical composition of Claim 10 or 11, formulated in any form suitable for oral administration.

13 (Currently Amended). A method for a therapeutic treatment comprising administering to a subject in need an effective amount of a naturally occurring LMW-A3RAg for achieving a therapeutic effect,

Appln. No. 10/056,484  
Amendment dated July 30, 2004  
Reply to Office action of July 30, 2004

the therapeutic effect comprises inhibition of adenylate cyclase in target cells.

14 (Original). The method of Claim 13, wherein said LMW-A3RAg is administered in combination with an additional therapeutic treatment.

15 (Original). The method of Claim 13 or 14, wherein said LMW-A3RAg is administered orally to the subject in need.

16 (Original). A method for a therapeutic treatment comprising administering to a subject in need an effective amount of a molecule according to Claim 9.